NCT01197066View on ClinicalTrials.gov

Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Certolizumab Pegol

Certolizumab Pegol 200mg

Sponsors
All Listed Sponsors
lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY